A research programme by the Access to Medicine Foundation
  • News
  • Foundation to convene high-level meeting in M...
News - published on 28 Aug 2018

Foundation to convene high-level meeting in Mumbai on access to medicine and AMR

The Access to Medicine Foundation will be visiting Mumbai, India, next week for a one-day meeting with pharmaceutical companies to discuss strategies to improve access to medicine and combat AMR. 

The agenda is led by leadership panel discussions on priority topics, including innovations in anti-infective R&D, responsible manufacturing of pharmaceutical products and on-the-ground solutions to address the access problem in India and globally. The aim of the event is to share best practices and encourage mutual learning through open dialogue on improving access and combating AMR.

Pharmaceutical industry in India

The Indian pharmaceutical industry is the third largest in the world, with an annual turnover of over USD 20 billion. The industry has been growing at a rate of more than 15% over the past five years and the Indian pharmaceutical market is projected to grow to USD 55 billion by 2020. Many of the world’s major producers, especially of generic medicines, are located in India or have operations there. The strategies adopted by these companies will have a significant impact on access to medicine and AMR globally.

The event is for companies evaluated in the Foundation’s three research programmes: the Access to Medicine Index, the Access to Vaccines Index, and the Antimicrobial Resistance Benchmark. Between them, these research programmes report on the practice of eight of the largest India-based pharmaceutical companies: Aurobindo, Cipla, Dr. Reddy’s, Lupin, Macleods, Serum Institute of India, Sun Pharma and Wockhardt.  Earlier this year we published a briefing paper specifically looking at how the pharmaceutical industry can take action to combat this growing problem in India.

Read more about the event. 


Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.